SMILES,Name,Conditions,NCT_Number,Phases,Unapproval Probability,Approval Probability
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,_EXEMESTANE,OVARIAN CANCER,NCT04460807,Phase 3,0.16301864096823682,0.8369813590317631
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,_LETROZOLE,OVARIAN CANCER,NCT03378297,Early Phase 1,0.3716633468760789,0.6283366531239212
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,NEWLY DIAGNOSED MULTIPLE MYELOMA,NCT03742297,Phase 3,0.005807504133292108,0.994192495866708
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,DIFFUSE LARGE B CELL LYMPHOMA,NCT02767674,Phase 3,0.006900466458597479,0.9930995335414023
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,_DOCETAXEL,NEOPLASMS,NCT03693612,Phase 2,0.7268597350216889,0.2731402649783113
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,PROSTATE CANCER,NCT04194554,Phase 1|Phase 2,0.6783368229037773,0.3216631770962228
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,BREAST CANCER,NCT02826512,Phase 2,0.4928113936320361,0.5071886063679638
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,OVARIAN CANCER,NCT03464201,Phase 2,0.6448421912742722,0.3551578087257279
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,BREAST CANCER,NCT02955394,Phase 2,0.7129664782448457,0.2870335217551544
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,OVARIAN CANCER,NCT03814447,Early Phase 1,0.15271999382632626,0.8472800061736738
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,NEOPLASMS,NCT03967223,Phase 2,0.0970197052016882,0.9029802947983118
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,DIFFUSE LARGE B CELL LYMPHOMA,NCT02767674,Phase 3,0.014352351895212315,0.9856476481047878
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,PROSTATE CANCER,NCT03089203,Phase 1,0.12590051639933084,0.8740994836006689
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.24282388105699745,0.7571761189430027
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,HEMATOLOGICAL MALIGNANCY,NCT03344705,Phase 1,0.1060993627832884,0.8939006372167115
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,HEMATOLOGIC NEOPLASMS,NCT01374841,Phase 2,0.08419591710904271,0.9158040828909572
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,DIFFUSE LARGE B CELL LYMPHOMA,NCT04214626,Phase 2,0.04893205132374402,0.951067948676256
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,BREAST CANCER,NCT02897700,Phase 1,0.035140425502963944,0.9648595744970362
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,NCT01376427,Not Applicable,0.09934043584243613,0.9006595641575638
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.4552333979340522,0.5447666020659478
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,PERIPHERAL T CELL LYMPHOMA,NCT03321890,Phase 2,0.04893205132374402,0.951067948676256
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.4806356392907244,0.5193643607092756
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,HEMATOLOGICAL MALIGNANCY,NCT01349101,Phase 2,0.4158628255308383,0.5841371744691615
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,ACUTE MYELOID LEUKEMIA,NCT03467386,Phase 1,0.5206284422254137,0.4793715577745863
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,SEVERE APLASTIC ANEMIA,NCT02918292,Phase 2,0.5281140748532048,0.4718859251467952
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,LYMPHEDEMA,NCT04390685,Phase 1|Phase 2,0.20477328792765426,0.7952267120723456
CS(=O)(=O)OCCCCOS(C)(=O)=O,_BUSULFAN,LYMPHOMA,NCT03151876,Phase 2,0.15221037813221108,0.8477896218677888
CS(=O)(=O)OCCCCOS(C)(=O)=O,_BUSULFAN,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.3598922519413667,0.6401077480586332
CS(=O)(=O)OCCCCOS(C)(=O)=O,_BUSULFAN,HEMATOLOGICAL MALIGNANCY,NCT01349101,Phase 2,0.23058239730473265,0.7694176026952672
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,OVARIAN CANCER,NCT03814447,Early Phase 1,0.25707783582484145,0.7429221641751586
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,NEOPLASMS,NCT03967223,Phase 2,0.15551991067743354,0.8444800893225665
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.3936800123100657,0.6063199876899341
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,HEMATOLOGICAL MALIGNANCY,NCT03344705,Phase 1,0.15760163084520712,0.842398369154793
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,PERIPHERAL T CELL LYMPHOMA,NCT04083495,Phase 2,0.4414223755429164,0.5585776244570835
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,_PALBOCICLIB,OVARIAN CANCER,NCT03936270,Phase 2,0.6875683909207397,0.3124316090792605
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,_PALBOCICLIB,PROSTATE CANCER,NCT02905318,Phase 2,0.698124530493636,0.3018754695063643
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,_VINORELBINE,MULTIPLE MYELOMA,NCT03442673,Phase 2,0.4764161570769653,0.5235838429230347
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,_VINORELBINE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT02733380,Phase 2,0.5216919200531507,0.4783080799468493
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,DIFFUSE LARGE B CELL LYMPHOMA,NCT02767674,Phase 3,0.08425713818209199,0.915742861817908
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,MULTIPLE MYELOMA,NCT03442673,Phase 2,0.17491443367829754,0.8250855663217024
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT04182204,Phase 3,0.2737269394913052,0.7262730605086944
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,NK/T CELL LYMPHOMA,NCT04230330,Phase 1,0.3225136763197545,0.6774863236802452
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,METASTATIC BREAST CANCER,NCT03901339,Phase 3,0.2737269394913052,0.7262730605086944
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,NEOPLASMS,NCT03693612,Phase 2,0.4890144111506733,0.5109855888493268
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1,_EPIRUBICIN,DIFFUSE LARGE B CELL LYMPHOMA,NCT02767674,Phase 3,0.030604438208244718,0.9693955617917552
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,OVARIAN CANCER,NCT03378297,Early Phase 1,0.7124820523238901,0.28751794767611005
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,PROSTATE CANCER,NCT03810105,Phase 2,0.8174147100089462,0.18258528999105386
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,_ENTINOSTAT,MYELODYSPLASTIC SYNDROME,NCT02936752,Phase 1,0.973944126471444,0.02605587352855608
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,_ENTINOSTAT,ACUTE MYELOID LEUKEMIA,NCT01305499,Phase 2,0.5705324635707629,0.4294675364292369
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,_MITOXANTRONE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT02733380,Phase 2,0.2487367621766743,0.7512632378233255
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT03913559,Phase 2,0.5752917574507915,0.4247082425492086
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,MULTIPLE MYELOMA,NCT03110822,Phase 1,0.5424037519738308,0.4575962480261692
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,_VANCOMYCIN,ULCERATIVE COLITIS,NCT03759041,Phase 2,0.27588584001016025,0.7241141599898399
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,_MYCOPHENOLATE_MOFETIL,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.5883964207613839,0.4116035792386162
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,_MYCOPHENOLATE_MOFETIL,HEMATOLOGICAL MALIGNANCY,NCT01349101,Phase 2,0.4563464617198973,0.5436535382801027
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,_MYCOPHENOLATE_MOFETIL,ACUTE MYELOID LEUKEMIA,NCT02782546,Phase 2,0.5905911425613759,0.4094088574386241
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,_MYCOPHENOLATE_MOFETIL,SEVERE APLASTIC ANEMIA,NCT02918292,Phase 2,0.6663584378598302,0.3336415621401699
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,BREAST CANCER,NCT01646034,Phase 3,0.13826797741687127,0.8617320225831286
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,SICKLE CELL DISEASE,NCT04362293,Phase 2,0.2608261344515561,0.7391738655484439
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.36009049872961896,0.6399095012703808
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,SEVERE APLASTIC ANEMIA,NCT02979873,Phase 2,0.3670015480263477,0.6329984519736521
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,BETA-THALASSEMIA,NCT03877809,Phase 2,0.13559764338550306,0.8644023566144969
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,_CLADRIBINE,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT03318419,Phase 2,0.26548925928903433,0.7345107407109656
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,_CLADRIBINE,LYMPHOMA,NCT03151876,Phase 2,0.2252454574369654,0.7747545425630346
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,_CYTARABINE,DIFFUSE LARGE B CELL LYMPHOMA,NCT03072771,Phase 1,0.43679537929571816,0.5632046207042819
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,_CYTARABINE,MYELODYSPLASTIC SYNDROME,NCT03412266,Phase 2,0.03913607238162989,0.96086392761837
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,_ELTROMBOPAG,ACUTE MYELOID LEUKEMIA,NCT03603795,Phase 2,0.1918287769056276,0.8081712230943724
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,_ELTROMBOPAG,SEVERE APLASTIC ANEMIA,NCT04304820,Phase 2,0.4331423568459388,0.5668576431540613
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,NEWLY DIAGNOSED MULTIPLE MYELOMA,NCT03742297,Phase 3,0.15931183224851142,0.8406881677514888
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,DIFFUSE LARGE B CELL LYMPHOMA,NCT03072771,Phase 1,0.645560657105023,0.354439342894977
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.4215564606678575,0.5784435393321423
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,ACUTE MYELOID LEUKEMIA,NCT02771197,Phase 2,0.645560657105023,0.354439342894977
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,_VEDOTIN,DIFFUSE LARGE B-CELL LYMPHOMA,NCT04182204,Phase 3,0.5319161832408185,0.4680838167591817
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,_VINCRISTINE,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,NCT01376427,Not Applicable,0.20713679227483606,0.7928632077251639
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,PROSTATE CANCER,NCT00859781,Phase 2,0.4196802699550157,0.5803197300449843
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,SEPSIS,NCT04160676,Not Applicable,0.11497273376739432,0.8850272662326057
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,_ETOPOSIDE,DIFFUSE LARGE B CELL LYMPHOMA,NCT03072771,Phase 1,0.5119512697625725,0.4880487302374275
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISOLONE,CARDIAC SARCOIDOSIS,NCT03705884,Not Applicable,0.06984966380299111,0.9301503361970088
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,_AZATHIOPRINE,SICKLE CELL DISEASE,NCT04362293,Phase 2,0.30790916052490064,0.6920908394750994
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,PROSTATE CANCER,NCT03513211,Phase 1|Phase 2,0.16185872544569052,0.8381412745543095
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,MULTIPLE MYELOMA,NCT04163107,Phase 1,0.2734283307524267,0.7265716692475734
CC(=O)Nc1ccc(O)cc1,_ACETAMINOPHEN,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT03913559,Phase 2,0.6810849187433928,0.3189150812566073
CC(=O)Nc1ccc(O)cc1,_ACETAMINOPHEN,MULTIPLE MYELOMA,NCT04268498,Phase 2,0.1386896871023452,0.8613103128976546
CN(C)CCOC(c1ccccc1)c1ccccc1,_DIPHENHYDRAMINE,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT03913559,Phase 2,0.5277963983350432,0.4722036016649567
CN(C)CCOC(c1ccccc1)c1ccccc1,_DIPHENHYDRAMINE,MULTIPLE MYELOMA,NCT04268498,Phase 2,0.1909376766734631,0.809062323326537
CNNCc1ccc(C(=O)NC(C)C)cc1,_PROCARBAZINE,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,NCT03495960,Phase 2,0.20100388954296708,0.7989961104570331
O=P1(NCCCl)OCCCN1CCCl,_IFOSFAMIDE,DIFFUSE LARGE B CELL LYMPHOMA,NCT03736616,Phase 2,0.3910000452734929,0.6089999547265073
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,NCT01376427,Not Applicable,0.025427774805770246,0.9745722251942298
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT02733380,Phase 2,0.03094940613608244,0.9690505938639176
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,NK/T CELL LYMPHOMA,NCT04230330,Phase 1,0.10569330767005164,0.8943066923299483
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,LYMPHOMA,NCT02436707,Phase 2,0.14190640571628232,0.8580935942837177
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,WALDENSTRÖM MACROGLOBULINEMIA,NCT04463953,Phase 2,0.03094940613608244,0.9690505938639176
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,_FOLIC_ACID,ANEMIA,NCT04404751,Not Applicable,0.1484689477510245,0.8515310522489754
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,_BIOTIN,ANEMIA,NCT02757898,Phase 1,0.7608103687534786,0.23918963124652134
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,_BIOTIN,SICKLE CELL DISEASE|SICKLE CELL ANEMIA,NCT04476277,Early Phase 1,0.7793764194547224,0.22062358054527764
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,_ASCORBIC_ACID,SEPSIS,NCT04160676,Not Applicable,0.105680880158836,0.8943191198411641
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,_AZACITIDINE,PERIPHERAL T CELL LYMPHOMA,NCT04480125,Phase 2,0.22947524462232646,0.7705247553776736
Cn1nnc2c(C(N)=O)ncn2c1=O,_TEMOZOLOMIDE,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,NCT03495960,Phase 2,0.3411485549827025,0.6588514450172974
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,_LENALIDOMIDE,DIFFUSE LARGE B CELL LYMPHOMA,NCT04214626,Phase 2,0.20223602504219493,0.7977639749578053
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,_LENALIDOMIDE,MANTLE CELL LYMPHOMA,NCT04109872,,0.24003130874299766,0.7599686912570024
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,_LENALIDOMIDE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT04404283,Phase 3,0.24955727711018105,0.7504427228898187
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,_LENALIDOMIDE,NON HODGKIN LYMPHOMA,NCT02180711,Phase 1|Phase 2,0.28907766549052866,0.7109223345094712
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,_POMALIDOMIDE,RELAPSED OR REFRACTORY MULTIPLE MYELOMA,NCT04191616,Phase 2,0.7777194254222985,0.22228057457770095
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,BREAST CANCER,NCT02790580,Phase 2,0.32318567043093793,0.6768143295690617
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,_RUXOLITINIB,MULTIPLE MYELOMA,NCT03110822,Phase 1,0.6696387302295116,0.33036126977048874
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,_RUXOLITINIB,LYMPHOMA,NCT02974647,Phase 2,0.535261171381372,0.464738828618628
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,_RUXOLITINIB,MALARIA,NCT04456634,Phase 1,0.22216075637156502,0.7778392436284348
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,_RUXOLITINIB,HODGKIN LYMPHOMA,NCT03681561,Phase 1|Phase 2,0.7754443170562721,0.22455568294372769
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,_DOXORUBICIN,METASTATIC BREAST CANCER,NCT04159818,Phase 2,0.14770377520331954,0.8522962247966803
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,_DOXORUBICIN_HYDROCHLORIDE,OVARIAN CANCER,NCT04337632,Phase 3,0.0914757535792574,0.9085242464207424
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,_DOXORUBICIN_HYDROCHLORIDE,MANTLE CELL LYMPHOMA,NCT03710772,Phase 2,0.6183724317876715,0.3816275682123288
COC(=O)C(c1ccccc1)C1CCCCN1,_METHYLPHENIDATE,ANXIETY,NCT02153944,Not Applicable,0.3015513155703675,0.6984486844296324
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,PROSTATE CANCER,NCT03769766,Phase 3,0.400774850005927,0.5992251499940731
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,BREAST CANCER,NCT03980509,Phase 1,0.8084904965373961,0.1915095034626039
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,ULCERATIVE COLITIS,NCT02277223,Phase 3,0.25461855130206196,0.7453814486979381
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,_VITAMIN_E,BREAST CANCER,NCT04463459,Not Applicable,0.18225834035808935,0.8177416596419104
CN(C)C(=N)NC(=N)N,_METFORMIN,OVARIAN CANCER,NCT03378297,Early Phase 1,0.2425002219012148,0.757499778098785
CN(C)C(=N)NC(=N)N,_METFORMIN,BREAST CANCER,NCT04559308,Phase 2,0.10789154677836804,0.8921084532216321
CN(C)C(=N)NC(=N)N,_METFORMIN,HEART FAILURE,NCT03331861,Phase 2,0.2880792683097751,0.711920731690225
CN(C)C(=N)NC(=N)N,_METFORMIN,RHEUMATOID ARTHRITIS,NCT04068246,Early Phase 1,0.11762768309763527,0.8823723169023647
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,_PEMETREXED,NEOPLASMS,NCT02964013,Phase 1,0.7006260673216869,0.29937393267831325
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,_PEMETREXED,CARCINOMA|NON-SMALL-CELL LUNG,NCT03952403,Phase 3,0.5318629615516026,0.4681370384483974
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,OVARIAN CANCER,NCT03378297,Early Phase 1,0.2868993502799984,0.7131006497200016
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,SEPSIS,NCT01784159,Phase 2,0.08382550565699479,0.9161744943430054
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",NCT04160546,Phase 2,0.3518475729717991,0.6481524270282008
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,OVARIAN CANCER,NCT03378297,Early Phase 1,0.2868993502799984,0.7131006497200016
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,SEPSIS,NCT01784159,Phase 2,0.08382550565699479,0.9161744943430054
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",NCT04160546,Phase 2,0.3518475729717991,0.6481524270282008
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,_PENTOXIFYLLINE,SCHIZOPHRENIA,NCT04094207,Phase 1|Phase 2,0.2832744779143658,0.7167255220856343
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,_PENTOXIFYLLINE,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT02451774,Phase 2|Phase 3,0.2955561334738185,0.7044438665261815
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,_ATORVASTATIN,BREAST CANCER,NCT02958852,Phase 2,0.2632982347195593,0.7367017652804406
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,MULTIPLE MYELOMA,NCT04268498,Phase 2,0.3656795421072879,0.6343204578927119
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,RHEUMATOID ARTHRITIS,NCT03770923,Phase 3,0.3656795421072879,0.6343204578927119
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,PAIN,NCT02793375,Phase 3,0.4606008424140982,0.5393991575859018
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,BREAST CANCER,NCT04172220,Not Applicable,0.2508758059898957,0.7491241940101044
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,FATIGUE,NCT04141696,Phase 1|Phase 2,0.6134325929699191,0.386567407030081
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,_SIMVASTATIN,LYMPHOMA,NCT04514029,Early Phase 1,0.9808078924248064,0.01919210757519376
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,_BORTEZOMIB,DIFFUSE LARGE B CELL LYMPHOMA,NCT03129828,Phase 1|Phase 2,0.2697784481795897,0.73022155182041
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,_BORTEZOMIB,HEMATOLOGICAL MALIGNANCY,NCT03850366,Phase 2,0.4933568195065535,0.5066431804934466
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,_BORTEZOMIB,ACUTE MYELOID LEUKEMIA,NCT04173585,Phase 2,0.13056479680384614,0.8694352031961536
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,_DASATINIB,ACUTE MYELOID LEUKEMIA,NCT02013648,Phase 3,0.21266030044371947,0.7873396995562802
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,_DASATINIB,"MYELOID LEUKEMIA, CHRONIC",NCT02890784,Phase 3,0.21266030044371947,0.7873396995562802
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,_PONATINIB,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",NCT04160546,Phase 2,0.8478830939348607,0.15211690606513947
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,_TRAMETINIB,MULTIPLE MYELOMA,NCT03091257,Phase 1,0.7831164442952165,0.21688355570478332
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,_DABRAFENIB,MULTIPLE MYELOMA,NCT03091257,Phase 1,0.6859020278090755,0.31409797219092456
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,_IDELALISIB,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT03742323,Phase 1|Phase 2,0.7177918991206451,0.282208100879355
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,_VENETOCLAX,BREAST CANCER,NCT04298918,Phase 1|Phase 2,0.9886548018270196,0.01134519817298067
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,_VENETOCLAX,MANTLE CELL LYMPHOMA,NCT03523975,Phase 1,0.944377867382704,0.05562213261729603
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,_VENETOCLAX,MYELODYSPLASTIC SYNDROME,NCT02942290,Phase 1,0.9453119998952466,0.05468800010475364
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,_LORLATINIB,ADVANCED CANCERS,NCT03726333,Phase 1,0.6425442718686682,0.3574557281313318
COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,_COPANLISIB,DIFFUSE LARGE B CELL LYMPHOMA,NCT04263584,Phase 2,0.8425103454052768,0.15748965459472303
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,BREAST CANCER,NCT04170465,Phase 2,0.3464750719071867,0.6535249280928129
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,HEART FAILURE,NCT03331861,Phase 2,0.4953262650904303,0.5046737349095697
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,_CARFILZOMIB,NEWLY DIAGNOSED MULTIPLE MYELOMA,NCT03742297,Phase 3,0.21784184799099685,0.7821581520090028
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,_CARFILZOMIB,MANTLE CELL LYMPHOMA,NCT03891355,Phase 2,0.2377750710925139,0.7622249289074858
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,_CARFILZOMIB,MULTIPLE MYELOMA,NCT03989414,Phase 1|Phase 2,0.2486680551214214,0.7513319448785784
O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1,_CC-220,MULTIPLE MYELOMA,NCT02773030,Phase 1|Phase 2,0.7774341082900709,0.22256589170992944
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,_IXAZOMIB,MANTLE CELL LYMPHOMA,NCT03616782,Phase 2,0.4631996388774042,0.5368003611225958
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,_THALIDOMIDE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT02733380,Phase 2,0.13854189171069994,0.8614581082892998
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,_THALIDOMIDE,THALASSEMIA,NCT03651102,Phase 2|Phase 3,0.16214785355522826,0.8378521464447714
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,_VINDESINE,DIFFUSE LARGE B CELL LYMPHOMA,NCT02767674,Phase 3,0.15176534162264058,0.8482346583773592
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,DIFFUSE LARGE B CELL LYMPHOMA,NCT03129828,Phase 1|Phase 2,0.2407582399209197,0.7592417600790804
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,PROSTATE CANCER,NCT02643667,Phase 1|Phase 2,0.6141721426100989,0.3858278573899011
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,LYMPHOMA,NCT02436707,Phase 2,0.3834911495596479,0.6165088504403518
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,NON-HODGKIN'S LYMPHOMA,NCT03198026,Phase 2,0.6095866699229792,0.39041333007702095
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,_DUVELISIB,PERIPHERAL T CELL LYMPHOMA,NCT03372057,Phase 2,0.9719627050710391,0.02803729492896096
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,_DECITABINE,HODGKIN LYMPHOMA,NCT03250962,Phase 2,0.03655307248062396,0.963446927519376
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,_DECITABINE,NON HODGKIN LYMPHOMA,NCT04337606,Phase 1|Phase 2,0.1431525053407222,0.8568474946592778
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,_BENDAMUSTINE,DIFFUSE LARGE B CELL LYMPHOMA,NCT02753062,Phase 2,0.4236484772015436,0.5763515227984564
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,_BENDAMUSTINE,MULTIPLE MYELOMA,NCT04083898,Phase 1|Phase 2,0.6252930843344816,0.37470691566551856
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,_BENDAMUSTINE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT02763319,Phase 2|Phase 3,0.2385440652773565,0.7614559347226434
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,_BENDAMUSTINE,PERIPHERAL T CELL LYMPHOMA,NCT04083495,Phase 2,0.6749163178398403,0.32508368216015954
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,_DOXYCYCLINE,ULCERATIVE COLITIS,NCT02606032,Phase 2,0.08555475285684846,0.9144452471431516
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,_DOXYCYCLINE,"LYMPHOMA, T-CELL, CUTANEOUS",NCT03116659,Early Phase 1,0.5673404604223038,0.4326595395776961
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,_TOPIRAMATE,SCHIZOPHRENIA,NCT02808533,Not Applicable,0.263690407690799,0.7363095923092007
CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,_POSACONAZOLE,INVASIVE ASPERGILLOSIS,NCT04218851,Phase 2,0.2584715057146193,0.7415284942853808
CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O,_CASPOFUNGIN,FUNGAL INFECTION,NCT03857399,Phase 2,0.2418841869367873,0.7581158130632126
CCCC(CCC)C(=O)O,_VALPROIC_ACID,ACUTE MYELOID LEUKEMIA,NCT01369368,Phase 1|Phase 2,0.3362634816910942,0.6637365183089059
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,_PYRIMETHAMINE,MYELODYSPLASTIC SYNDROME,NCT03057990,Phase 1,0.7014425740408555,0.29855742595914475
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,_IVERMECTIN,MALARIA,NCT03967054,Phase 3,0.017671707791450334,0.9823282922085496
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,SCHIZOPHRENIA,NCT04369391,Phase 1,0.8088205294323348,0.1911794705676651
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,DIABETES,NCT01984827,Phase 1,0.5867924574085103,0.4132075425914897
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,_ROFLUMILAST,ASTHMA,NCT04108377,Phase 1,0.2851536163607538,0.7148463836392458
[Cl-].[Na+],_SODIUM_CHLORIDE,EPISTAXIS,NCT02930941,Not Applicable,0.20194325261821192,0.7980567473817881
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,ULCERATIVE COLITIS,NCT02606032,Phase 2,0.14621013039270214,0.8537898696072977
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,_LAMIVUDINE,CHRONIC LYMPHOCYTIC LEUKEMIA,NCT03528941,,0.3551527036211881,0.6448472963788118
CC[C@@H](C(N)=O)N1CCCC1=O,_LEVETIRACETAM,SCHIZOPHRENIA,NCT02647437,Not Applicable,0.5214005323048599,0.4785994676951401
CC(C)Cn1cnc2c(N)nc3ccccc3c21,_IMIQUIMOD,METASTATIC BREAST CANCER,NCT03982004,Phase 1,0.8408857869726108,0.15911421302738907
CC(C)Cn1cnc2c(N)nc3ccccc3c21,_IMIQUIMOD,"LYMPHOMA, T-CELL, CUTANEOUS",NCT03116659,Early Phase 1,0.8298775232925335,0.17012247670746622
O=NN(CCCl)C(=O)NCCCl,_CARMUSTINE,DIFFUSE LARGE B CELL LYMPHOMA,NCT03072771,Phase 1,0.9828705640273544,0.017129435972645414
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,_PLERIXAFOR,MULTIPLE MYELOMA,NCT03406091,,0.4236430061804228,0.5763569938195771
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,_PLERIXAFOR,SICKLE CELL DISEASE,NCT04362293,Phase 2,0.4752178394109775,0.5247821605890225
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,_ACALABRUTINIB,DIFFUSE LARGE B CELL LYMPHOMA,NCT03736616,Phase 2,0.7859346202506511,0.21406537974934892
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,_ACALABRUTINIB,NON HODGKIN LYMPHOMA,NCT02180711,Phase 1|Phase 2,0.8031510414651796,0.19684895853482046
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,_CARVEDILOL,PROSTATE CANCER,NCT02944201,Phase 2,0.6797634000444035,0.3202365999555967
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,_CARVEDILOL,BREAST CANCER,NCT03879629,Phase 2,0.7562026570383671,0.243797342961633
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O,_ETOPOSIDE_PHOSPHATE,LYMPHOMA,NCT02106988,Phase 2,0.7386243201024653,0.26137567989753485
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,_MOMETASONE,SICKLE CELL DISEASE,NCT03758950,Phase 2,0.5939630524522753,0.4060369475477247
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,_FENTANYL,HEART FAILURE,NCT02421341,Not Applicable,0.205598122541363,0.7944018774586368
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,_ONDANSETRON,BLOOD COAGULATION DISORDER,NCT04499274,Not Applicable,0.497496332979773,0.502503667020227
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,FATIGUE,NCT04141696,Phase 1|Phase 2,0.3402813646351697,0.6597186353648303
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,ACUTE MYELOID LEUKEMIA,NCT02942758,Phase 2,0.3750771953732318,0.6249228046267681
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,CHRONIC MYELOID LEUKEMIA,NCT02889003,Phase 2,0.5970869639787837,0.4029130360212163
CN(C)/N=N/c1[nH]cnc1C(N)=O,_DACARBAZINE,HODGKIN LYMPHOMA,NCT03033914,Phase 1|Phase 2,0.540079287544821,0.4599207124551791
O=S(=O)(O)CCS,_MESNA,LYMPHOMA,NCT02436707,Phase 2,0.18886437670048106,0.8111356232995189
O=S(=O)(O)CCS,_MESNA,SICKLE CELL DISEASE,NCT03263559,Phase 2,0.6323668329023178,0.3676331670976821
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,_SOFOSBUVIR,HEPATITIS B INFECTION,NCT03312023,Phase 2,0.5809850038824915,0.4190149961175084
COC(=O)N[C@H](C(=O)N1CC2(CC2)C[C@H]1c1nc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5[nH]c([C@@H]6[C@H]7CC[C@H](C7)N6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc2-3)c[nH]1)C(C)C,_LEDIPASVIR,HEPATITIS B INFECTION,NCT03312023,Phase 2,0.6928542047859615,0.3071457952140386
NC[C@H]1CC[C@H](C(=O)O)CC1,_TRANEXAMIC_ACID,EPISTAXIS,NCT02930941,Not Applicable,0.1983696975657406,0.8016303024342594
OCC(O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,_ISOMALT,IRON DEFICIENCY ANEMIA TREATMENT,NCT03610230,Not Applicable,0.14027228846416245,0.8597277115358374
O.O.O.O.O.O=S([O-])([O-])=S.[Na+].[Na+],_SODIUM_THIOSULFATE,CENTRAL NERVOUS SYSTEM LYMPHOMA,NCT00293475,Phase 1|Phase 2,0.9164419108420732,0.08355808915792702
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,_VANDETANIB,NEOPLASMS,NCT02530411,Phase 2,0.6505748898611121,0.3494251101388878
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,_LORATADINE,EOSINOPHILIC ESOPHAGITIS,NCT04248712,Phase 2,0.5628225942389776,0.4371774057610224
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,_CRIZOTINIB,NEOPLASMS,NCT03194893,Phase 3,0.41296364604366176,0.587036353956338
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,_TOPOTECAN,OVARIAN CANCER,NCT03763123,Phase 1,0.5888766525168381,0.41112334748316204
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,_MARAVIROC,STROKE,NCT03172026,Phase 2|Phase 3,0.5503577533772205,0.4496422466227796
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_ALBUTEROL,MYASTHENIA GRAVIS,NCT03914638,Phase 2|Phase 3,0.2145534935024929,0.7854465064975069
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_SALBUTAMOL,MYASTHENIA GRAVIS,NCT03914638,Phase 2|Phase 3,0.2145534935024929,0.7854465064975069
O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,_PALONOSETRON,BLOOD COAGULATION DISORDER,NCT04507711,Not Applicable,0.43595533958343613,0.5640446604165639
NCCCC[C@H](N)C(=O)O,_LYSINE,HEART FAILURE,NCT03446651,Early Phase 1,0.6174295147779739,0.3825704852220264
COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,_RIOCIGUAT,SICKLE CELL DISEASE,NCT02633397,Phase 2,0.3335880909408374,0.6664119090591627
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,_FUROSEMIDE,NEPHROTIC SYNDROME,NCT03750136,Not Applicable,0.42064915020895866,0.5793508497910413
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,SICKLE CELL DISEASE,NCT03978156,Phase 1,0.41980535398579705,0.5801946460142029
CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,_UMBRALISIB,CHRONIC LYMPHOCYTIC LEUKEMIA,NCT04016805,Phase 2,0.7997382241060982,0.20026177589390196
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,_RIBAVIRIN,ACUTE MYELOID LEUKEMIA,NCT03760666,Phase 1|Phase 2,0.14204268948759233,0.8579573105124075
NC(=O)NO,_HYDROXYUREA,SICKLE CELL DISEASE,NCT04362293,Phase 2,0.3627812418246832,0.6372187581753168
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,_URSODIOL,LIVER DISEASES,NCT02943707,Phase 2,0.1734749405677359,0.8265250594322642
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,_URSODEOXYCHOLIC_ACID,LIVER DISEASES,NCT02943707,Phase 2,0.1734749405677359,0.8265250594322642
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,_BOSUTINIB,CHRONIC MYELOID LEUKEMIA,NCT03831776,Phase 2,0.35897861968910555,0.6410213803108941
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,_BOSUTINIB,CHRONIC MYELOGENOUS LEUKEMIA,NCT02501330,,0.35177008500674345,0.6482299149932562
OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)C[C@@H]1O,_PENTOSTATIN,SICKLE CELL DISEASE,NCT03077542,Phase 1|Phase 2,0.5692087138044815,0.4307912861955184
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,_RIMIDUCID,MULTIPLE MYELOMA,NCT03288493,Phase 1|Phase 2,0.8823931121760248,0.11760688782397515
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,_TUCIDINOSTAT,BREAST CANCER,NCT04465097,Phase 2,0.38354848356293497,0.6164515164370649
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,_TUCIDINOSTAT,DIFFUSE LARGE B-CELL LYMPHOMA,NCT04231448,Phase 3,0.4771749272533514,0.5228250727466486
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O,_RUXOLITINIB_PHOSPHATE,MALARIA,NCT04456634,Phase 1,0.37763638129964816,0.6223636187003521
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,_RUCAPARIB,BREAST CANCER,NCT03911453,Early Phase 1,0.7917348543608795,0.2082651456391204
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,_ZAFIRLUKAST,OVARIAN CANCER,NCT04339140,Phase 2,0.7811593377829661,0.21884066221703385
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,_FLUTICASONE,PHARMACOKINETICS,NCT03739294,Phase 2,0.2255294250365834,0.7744705749634165
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,_BARICITINIB,UVEITIS,NCT04088409,Phase 3,0.3814343040626212,0.618565695937379
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1,_RADOTINIB,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",NCT03722420,Phase 3,0.5781475363299448,0.4218524636700555
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,PROSTATE CANCER,NCT03716739,Phase 2,0.41034333872542456,0.5896566612745753
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,RHEUMATOID ARTHRITIS,NCT02680067,Phase 1,0.6530700752304105,0.3469299247695896
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,ENDOMETRIOSIS,NCT03950206,Not Applicable,0.332620361945084,0.6673796380549157
CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1,_GLASDEGIB,ACUTE MYELOID LEUKEMIA,NCT04051996,Phase 2,0.7858954870612439,0.21410451293875624
O=[N+]([O-])[O-],_NITRATE,HEART FAILURE,NCT02840799,Phase 2,0.30153908141284913,0.6984609185871506
CC(=O)C(=O)O,_PYRUVATE,PROSTATE CANCER,NCT02913131,Phase 1|Phase 2,0.6051315279605245,0.3948684720394756
CC(=O)C(=O)O,_PYRUVATE,BREAST CANCER,NCT03121989,Phase 1,0.2641269258615515,0.7358730741384485
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,_PACRITINIB,BREAST CANCER,NCT04520269,Phase 1|Phase 2,0.8250927159195842,0.1749072840804158
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,_DANAZOL,IMMUNE THROMBOCYTOPENIA,NCT04481282,Phase 2,0.5434327110232843,0.4565672889767158
CN1[C@H]2CCC[C@@H]1C[C@H](NC(=O)c1nn(C)c3ccccc13)C2,_GRANISETRON,SEPSIS,NCT03924518,Phase 2,0.13952368830585404,0.8604763116941458
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,_KETOTIFEN,FUNCTIONAL DYSPEPSIA,NCT02484248,Phase 3,0.4284262447043679,0.5715737552956319
CN(C)CCC=C1c2ccccc2COc2ccccc21,_DOXEPIN,BREAST CANCER,NCT02447211,Phase 2,0.2804038369297273,0.7195961630702726
Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,_TOMIVOSERTIB,BREAST CANCER,NCT04261218,Phase 1,0.7728802241651735,0.22711977583482645
CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1,_SAPACITABINE,BREAST CANCER,NCT03641755,Phase 1|Phase 2,0.922049517728428,0.07795048227157197
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_SUCROSE,PAIN,NCT04313179,Not Applicable,0.06084270219419781,0.9391572978058024
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_SUCROSE,IRON DEFICIENCY ANEMIA TREATMENT,NCT03610230,Not Applicable,0.024632531321876032,0.975367468678124
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_SUCROSE,"ANEMIA, IRON DEFICIENCY",NCT03917394,,0.09737120573495986,0.9026287942650402
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],_IRON_SUCROSE,IRON DEFICIENCY ANEMIA TREATMENT,NCT03610230,Not Applicable,0.02364883125341658,0.9763511687465832
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],_IRON_SUCROSE,"ANEMIA, IRON DEFICIENCY",NCT03917394,,0.10554469265285277,0.8944553073471471
O=C([O-])/C=C/C(=O)[O-].[Fe+2],_FERROUS_FUMARATE,"ANEMIA, IRON-DEFICIENCY",NCT04163406,Not Applicable,0.12299251498835187,0.8770074850116483
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Nc2ccc(O)cc2)C(C)(C)CCC1,_FENRETINIDE,PERIPHERAL T CELL LYMPHOMA,NCT02495415,Phase 2,0.8177099682209771,0.18229003177902287
CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,_TENALISIB,HEMATOLOGICAL MALIGNANCY,NCT03711604,Phase 1|Phase 2,0.7730838831009923,0.22691611689900784
CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,_TENALISIB,"LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL",NCT04204057,Phase 2,0.7730838831009923,0.22691611689900784
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,_FLUTICASONE_FUROATE,PHARMACOKINETICS,NCT03739294,Phase 2,0.2974667638998844,0.7025332361001153
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,_CANAGLIFLOZIN,HEART FAILURE,NCT04252287,Phase 3,0.6532493157198664,0.3467506842801337
O=N[O-],_NITRITE,HEART FAILURE,NCT02713126,Phase 2,0.5108077277532381,0.4891922722467619
O=N[O-].[Na+],_SODIUM_NITRITE,HEART FAILURE,NCT02713126,Phase 2,0.7874929552135742,0.21250704478642612
CCCCCCCCCCCCCCCC(=O)NCC(O)COP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2ccc(N)nc2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1N,_IMETELSTAT,MYELODYSPLASTIC SYNDROME,NCT02598661,Phase 2|Phase 3,0.6406715128614305,0.3593284871385694
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,_VOXELOTOR,SICKLE CELL DISEASE,NCT04247594,Phase 2,0.3499791415537177,0.6500208584462821
NC(=O)OCC(COC(N)=O)c1ccccc1,_FELBAMATE,EPILEPSY,NCT03196466,,0.390405985470746,0.6095940145292541
CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1,_CARIPRAZINE,SCHIZOPHRENIA,NCT03817502,Phase 3,0.4716871540842461,0.5283128459157538
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,_ALPELISIB,BREAST CANCER,NCT03056755,Phase 2,0.6900624582914029,0.3099375417085971
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,_ERDAFITINIB,METASTATIC BREAST CANCER,NCT03238196,Phase 1,0.8221446647008125,0.1778553352991875
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,_ERDAFITINIB,RELAPSED REFRACTORY MULTIPLE MYELOMA,NCT03732703,Phase 1|Phase 2,0.8107488722514924,0.18925112774850766
CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,_DAROLUTAMIDE,PROSTATE CANCER,NCT04136353,Phase 3,0.5228872284733456,0.4771127715266546
CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,_ENASIDENIB,ACUTE MYELOID LEUKEMIA,NCT04075747,Phase 1,0.7004529793250827,0.2995470206749175
CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,_ENASIDENIB,RELAPSED REFRACTORY MULTIPLE MYELOMA,NCT03732703,Phase 1|Phase 2,0.6791335856901543,0.3208664143098457
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,_ZANUBRUTINIB,DIFFUSE LARGE B CELL LYMPHOMA,NCT04460248,Phase 2,0.3451466417909552,0.6548533582090448
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,_ZANUBRUTINIB,WALDENSTRÖM MACROGLOBULINEMIA,NCT04463953,Phase 2,0.3830332495463819,0.6169667504536179
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,_UPADACITINIB,ULCERATIVE COLITIS,NCT03006068,Phase 3,0.5854105210586142,0.4145894789413858
